S&P Global and CME Group to sell OSTTRA to KKR for $3.1 billion

Core Viewpoint - S&P Global and CME Group have signed a definitive agreement to sell OSTTRA, a provider of post-trade solutions for the global OTC market, to KKR for a total enterprise value of $3.1 billion, with the proceeds split evenly between the two companies [1]. Company Overview - OSTTRA was established in 2021 as a joint venture between CME Group and S&P Global, offering a comprehensive suite of post-trade solutions across various asset classes including interest rates, FX, credit, and equity [2][8]. - The company processes over 80 million trades monthly, establishing itself as a critical infrastructure provider in the post-trade space [8]. Management and Future Plans - The current management team of OSTTRA, led by co-CEOs Guy Rowcliffe and John Stewart, will continue in their roles post-acquisition [3]. - KKR plans to support OSTTRA's growth by increasing investments in technology and innovation, enhancing its market-leading post-trade solutions [3][4]. Strategic Insights - KKR's investment strategy includes creating an equity ownership program for OSTTRA's nearly 1,500 employees, promoting engagement through ownership [4]. - The transaction is expected to close in the second half of 2025, pending regulatory approvals [5]. Advisory Roles - Financial and legal advisors for the transaction include Barclays and Davis Polk for S&P Global, Citi and Skadden for CME Group, and Goldman Sachs and Simpson Thacher & Bartlett for KKR [5].